Skip to main content

Advertisement

SpringerLink
Log in

Update on the Sexual Impact of Treatment for Benign Prostatic Hyperplasia

  • Benign Prostatic Hyperplasia (K McVary, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

There is an established link between lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). The medical and surgical management of LUTS can affect erectile function (EF), cause ejaculatory dysfunction (EjD) or affect libido. This article will review the effects of these therapies on sexual function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.

    PubMed  CAS  Google Scholar 

  2. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150:546–51.

    PubMed  CAS  Google Scholar 

  3. •• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803. This AUA update provides an excellent review of the treatment of BPH.

    Article  PubMed  Google Scholar 

  4. Roehrborn CG. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol. 2009;11 Suppl 1:S1–8.

    PubMed  Google Scholar 

  5. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171(3):1029–35.

    Article  PubMed  CAS  Google Scholar 

  6. American Urological Association: AUA Guidelines on Management of Benign Prostatic Hyperplasia, 2003, revision 2006. Chapter 3. Available at http://www.auanet.org.

  7. De la Rosette JJ, Kortmass BB, Rossi C. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol. 2002;167(4):1734–9.

    Article  PubMed  Google Scholar 

  8. Hellstrom WJ, Sikka SC. Effects of acute urinary retention with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006;176:1529–33.

    Article  PubMed  CAS  Google Scholar 

  9. Nagai A, Hara R, Yokoyama T. Ejaculatory dysfunction caused by the new alpha-blocker silodosin: a preliminary study to analyze human circulation using color Doppler ultrasonography. Int J Urol. 2008;15:915–8.

    Article  PubMed  Google Scholar 

  10. Hisasue S, Furuya R, Itoh N. Ejaculatory disorder caused by alpha 1 adrenoreceptor antagonists is not retrograde ejaculation by a loss of seminal emission. Int J Urol. 2006;13:1311–6.

    Article  PubMed  CAS  Google Scholar 

  11. Kobayashi K, Masumori N, Hisasue S. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha 1A blocker in normal volunteers. J Sex Med. 2008;5:2185–90.

    Article  PubMed  Google Scholar 

  12. Kirby RS, Roehrborn C, Hoyle P. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119–26.

    Article  PubMed  Google Scholar 

  13. Lepor H, Williford WO, Barry MJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335:533–9.

    Article  PubMed  CAS  Google Scholar 

  14. Van Kerrebroeck P, Jardin A, Laval KU. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfusozin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37:306–13.

    Article  PubMed  Google Scholar 

  15. Van Kerrebroeck P, Jardin A, van Cangh P. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol. 2002;41:54–60.

    Article  Google Scholar 

  16. Elhilali M, Emberton M, Matzkin H. Long-term efficacy and safety of alfuzosing 10 mg once-daily: a 2-year experience in “real-life” practice. BJU Int. 2006;97:513–9.

    Article  PubMed  CAS  Google Scholar 

  17. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 1998;160:1701–6.

    Article  PubMed  CAS  Google Scholar 

  18. Höfner K, Claes H, De Reijke TM. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36:335–41.

    Article  PubMed  Google Scholar 

  19. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of highly selective alpha1A-adenoreceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: polled results of 2 phase 3 studies. J Urol. 2009;181:2634.

    Article  PubMed  CAS  Google Scholar 

  20. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology. 1998;51:677–86.

    Article  PubMed  CAS  Google Scholar 

  21. Roehrborn CG, Boyle P, Nickel JC. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:431–41.

    Article  Google Scholar 

  22. Roehrborn CG, Marks LS, Fenter T. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63:709–15.

    Article  PubMed  Google Scholar 

  23. Dorsam J, Altwein J. 5 alpha-reductase inhibitor treatment of prostatic diseases: background and practical implications. Prostate Cancer Prostatic Dis. 2009;12(2):130–6.

    Article  PubMed  CAS  Google Scholar 

  24. Andersen JT, Ekman P, Wolf H. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo controlled study. Urology. 1995;46:631.

    Article  PubMed  CAS  Google Scholar 

  25. McConnell JD, Bruskewitz R, Walsh P. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557–63.

    Article  PubMed  CAS  Google Scholar 

  26. Traish AM, Hassani J, Guay AT. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872–84.

    Article  PubMed  CAS  Google Scholar 

  27. McConnell JD, Roehrbon CG, Bautista OM. The long-term effect of doxasozin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387.

    Article  PubMed  CAS  Google Scholar 

  28. •• Roehrborn CG, Siami P, Barkin J. The effects of combination therapy with duatsteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123. The CombAT study has had tremendous impact on the treatment of BPH with combination therapy. This article provides the 4 year data from this endeavor.

    Article  PubMed  Google Scholar 

  29. FDA: Postmarket Drug Safety Information for Patients and Providers, Cialis (tadalafil information). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.

  30. McVary KT, Roehrborn CG, Kaminetsky JC. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2007;177:1401–7.

    Article  CAS  Google Scholar 

  31. Roehrborn CG, McVary KT, Wlion-Mboussa A. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228–34.

    Article  PubMed  CAS  Google Scholar 

  32. Egerdie RB, Auerbach S, Roehrborn CG. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012;9:271–81.

    Article  PubMed  CAS  Google Scholar 

  33. Bechara A, Romano S, Casabé A. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med. 2008;5:2170–8.

    Article  PubMed  CAS  Google Scholar 

  34. Liguori G, Trombetta C, De Girorgi G. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patient with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009;6:544–52.

    Article  PubMed  CAS  Google Scholar 

  35. McVary KT, Monnig W, Camps Jr JL, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071.

    Article  PubMed  CAS  Google Scholar 

  36. Sairam K, Kulinskaya E, McNicholas TA. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836.

    Article  PubMed  CAS  Google Scholar 

  37. Mulhall JP, Guhring P, Parker M. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med. 2006;3:662.

    Article  PubMed  CAS  Google Scholar 

  38. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51(6):1717–23.

    Article  PubMed  CAS  Google Scholar 

  39. • Gacci M, Coronoa G, Salvi M. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994–1003. This review article provides relevant and recent data regarding the use of combination therapy involving PDE5 inhibitors in the treatment of men with BPH.

    Article  PubMed  CAS  Google Scholar 

  40. Stief CG, Porst H, Neuser D, et al. A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53(6):1236–44.

    Article  PubMed  CAS  Google Scholar 

  41. Kaplan SA, Roehrborn CG, Rovner ES. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA. 2006;296:2319–28 (Published errata appear in JAMA 2007, 297:1195 and JAMA 2007, 298:1864).

    Article  PubMed  CAS  Google Scholar 

  42. •• Kaplan SA, Roehrborn CG, Abrams P. Antimuscarinics for the treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65(4):487–507. This review article provides an excellent review of antimuscarinics and provides data on their safe use in the treatment of men with BPH.

    Article  PubMed  CAS  Google Scholar 

  43. Muntener M, Aellig S, Kuettel R, et al. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicenter assessment of outcome. Eur Urol. 2007;52:510–5 (Published errata appear in the Eur Urol 2008, 53:456).

    Article  PubMed  Google Scholar 

  44. Poulakis V, Ferakis N, Witzsch U, et al. Erectile dysfunction after transurethral prostatectomy for lower urinary tract symptoms: results from a center with over 500 patients. Asian J Androl. 2006;8:69–74.

    Article  PubMed  Google Scholar 

  45. • Jaidane M, Arfa NB, Hmida W, et al. Effect of transurethral resection of the prostate on erectile function: a prospective comparative study. Int J Impot Res. 2010;22:146–51. This study used TURBT as a sham study for comparison with TURP and its effects on erectile function.

    Article  PubMed  CAS  Google Scholar 

  46. Arai Y, Aoki Y, Okubo K, et al. Impact of interventional therapy for benign prostatic hypertrophy on quality of life and sexual function: a prospective study. J Urol. 2000;164:1206–11.

    Article  PubMed  CAS  Google Scholar 

  47. Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int. 2003;91:196–200.

    Article  PubMed  CAS  Google Scholar 

  48. Kavoussi PK, Hermans MR. Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hypertrophy. J Sex Med. 2008;5:2669–71.

    Article  PubMed  Google Scholar 

  49. Paick JS, Um JM, Kim SW, et al. Influence of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate on erectile function: a short-term follow-up study. J Sex Med. 2007;4:1701–7.

    Article  PubMed  Google Scholar 

  50. Wilson LC, Gilling PJ, Williams A, et al. A randomized trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50:569–73.

    Article  PubMed  Google Scholar 

  51. Briganti A, Naspro R, Gallina A, et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2 center, randomized trial. J Urol. 2006;175:1817–21.

    Article  PubMed  Google Scholar 

  52. Woo HH, Bolton DM, Laborde E, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:568–75.

    Article  PubMed  Google Scholar 

  53. •• Chin PT, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2011;5–11. This article provides 2 year data on the novel UroLift procedure.

  54. NeoTract UroLift Website. http://www.neotract.com/formedicalprofessionals_ous-q10095-c10049-UroLift_System.aspx.

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Urology, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA, 70121, USA

    John Roger Bell & Eric Laborde

Authors
  1. John Roger Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Laborde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Laborde.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bell, J.R., Laborde, E. Update on the Sexual Impact of Treatment for Benign Prostatic Hyperplasia. Curr Urol Rep 13, 433–440 (2012). https://doi.org/10.1007/s11934-012-0278-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-012-0278-5

Keywords

Search

Navigation